STAT+: What an abandoned heart failure trial says about ‘breakthrough’ devices that don’t reach patients

An abandoned heart-failure trial offers a rare window into devices that the FDA deems "breakthrough" but never reach patients.

CryptoAlerta — análise de criptomoedas e mercado em tempo real